Fate Therapeutics, Inc. (FATE) Financials

FATE Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 506.2 million 137.8 million
2023-09-30 543.8 million 141.0 million
2023-06-30 584.8 million 147.0 million
2023-03-31 630.3 million 152.9 million

FATE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -36.8 million 9.5 million
2023-09-30 -38.8 million 10.1 million
2023-06-30 -30.7 million 12.9 million
2023-03-31 -32.1 million 11.0 million

FATE Net Income

No data available :(

FATE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 315.2 million - 103.5 million
2023-09-30 349.7 million - 105.0 million
2023-06-30 377.9 million - 106.3 million
2023-03-31 408.9 million - 107.6 million

FATE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 98.6 million
2023-09-30 98.6 million
2023-06-30 98.4 million
2023-03-31 98.1 million

FATE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 181000 26.9 million 17.9 million -
2023-09-30 565000 34.3 million 18.9 million -
2023-06-30 2.2 million 40.9 million 22.6 million -
2023-03-31 3.2 million 65.6 million 21.9 million -

FATE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 1.7 million 4.9 million
2023-09-30 1.9 million 4.7 million
2023-06-30 933000 4.5 million
2023-03-31 59.0 million 4.2 million

FATE

Price: $4.22

52 week price:
1.63
8.83

Earnings Per Share: -1.64 USD

P/E Ratio: -3.92

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 1.6 million

Ebitda: -10.1 million

Market Capitalization: 465.4 million

Links: